Fatty Liver Disease Clinical Trials

136 recruitingLast updated: July 17, 2026

There are 136 actively recruiting fatty liver disease clinical trials across 35 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 4, Phase 3, Early Phase 1. Top locations include Beijing, Beijing Municipality, China, San Antonio, Texas, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Fatty Liver Disease Trials at a Glance

136 actively recruiting trials for fatty liver disease are listed on ClinicalTrialsFinder across 6 cities in 35 countries. The largest study group is Not Applicable with 43 trials, with the heaviest enrollment activity in Beijing, San Antonio, and New York. Lead sponsors running fatty liver disease studies include GlaxoSmithKline, Cairo University, and Humanity and Health Research Centre.

Browse fatty liver disease trials by phase

Treatments under study

About Fatty Liver Disease Clinical Trials

Looking for clinical trials for Fatty Liver Disease? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Fatty Liver Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Fatty Liver Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 136 trials

Recruiting
Phase 2

Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

Non-Alcoholic Fatty Liver DiseaseNon Alcoholic Steatohepatitis
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)104 enrolled1 locationNCT03884075
Recruiting
Not Applicable

NAC- NAFLD And Cushing

Cushing SyndromeFatty Liver Disease
University Hospital, Angers100 enrolled7 locationsNCT05881005
Recruiting
Phase 2

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

Non-Alcoholic Fatty Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis
GlaxoSmithKline42 enrolled30 locationsNCT06920043
Recruiting
Not Applicable

Taiwan Green Propolis for Blood Lipids and Body Fat in Patients With MASLD

Obesity, OverweightMetabolic Dysfunction-Associated Steatotic Liver DiseaseNon-alcoholic Fatty Liver Disease NAFLD+1 more
Taipei Medical University60 enrolled1 locationNCT07692438
Recruiting
Phase 1

Effect of Insulin Lowering on Lipogenesis

ObesityInsulin ResistanceNon-Alcoholic Fatty Liver Disease+2 more
Columbia University25 enrolled1 locationNCT07403604
Recruiting
Not Applicable

Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients

Liver FibrosisNon-alcoholic Fatty Liver Disease NAFLDAlcoholic Liver Disease (ALD)
University Hospital, Angers1,788 enrolled13 locationsNCT05699018
Recruiting
Not Applicable

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

Insulin Sensitivity/ResistanceObesityInsulin Resistance+16 more
Pichamol Jirapinyo, MD, MPH132 enrolled2 locationsNCT06138821
Recruiting

Clinical Course and Biomarkers Associated With Nonalcoholic Fatty Liver Disease (NAFLD) in Chinese Patients With Obesity

Nonalcoholic Fatty Liver Disease (NAFLD)
Chinese University of Hong Kong200 enrolled1 locationNCT07662356
Recruiting

Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme

ObesityLiver FibrosisMetabolic Dysfunction-Associated Steatotic Liver Disease+3 more
Hospital General Universitario Gregorio Marañon3,000 enrolled1 locationNCT07658755
Recruiting
Not Applicable

Exploratory Study of MRI Biomarkers of NASH

Non-alcoholic Fatty Liver Disease NAFLD
University Hospital, Angers110 enrolled2 locationsNCT06626074
Recruiting

Increased Risk of Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals

Non-Alcoholic Fatty Liver DiseaseLow Birth Weight
Steno Diabetes Center Copenhagen300 enrolled1 locationNCT05890365
Recruiting
Phase 1

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

Non-Alcoholic Fatty Liver Disease
GlaxoSmithKline32 enrolled3 locationsNCT07358546
Recruiting

Investigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease
Queen Mary University of London153 enrolled1 locationNCT04141592
Recruiting

Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease

FibrosisNonalcoholic SteatohepatitisNonalcoholic Fatty Liver Disease+1 more
Peking Union Medical College Hospital2,000 enrolled1 locationNCT05330923
Recruiting

Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD

Type 2 Diabetes Mellitus (T2DM)MASH - Metabolic Dysfunction-Associated SteatohepatitisMetabolic Dysfunction-associated Fatty Liver Disease
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School10,000 enrolled22 locationsNCT07632677
Recruiting

A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes

NAFLD - Non-Alcoholic Fatty Liver DiseaseNAFLD and NASHNAFLD Cirrhosis
The Affiliated Hospital of Hangzhou Normal University20,000 enrolled1 locationNCT07241195
Recruiting
Not Applicable

The Evaluation of Orange Peel Fermentation on Body Fat Lowering Efficacy in Adults

OverweightFatty Liver Disease
TCI Co., Ltd.124 enrolled1 locationNCT04496895
Recruiting

Identification of Liver Fibrosis Biomarkers

Non-Alcoholic Fatty Liver DiseaseNon Alcoholic SteatohepatitisNon-alcoholic Fatty Liver
Roche Diagnostics GmbH575 enrolled2 locationsNCT06819917
Recruiting
Phase 2

Digoxin In NASH (CODIN)

MASLDMASH - Metabolic Dysfunction-Associated SteatohepatitisFatty Liver Disease+5 more
Yale University144 enrolled2 locationsNCT06588699
Recruiting
Phase 1

Evaluating the Pharmacokinetics and Safety of Miricorilant

Nonalcoholic Steatohepatitis (NASH)Non-alcoholic Fatty Liver Disease NAFLDMetabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis+1 more
Corcept Therapeutics15 enrolled1 locationNCT07553663